RxDoctor Payments Data

Thomas Weber, MD

Pulmonary Disease · Bryan, TXNPI 1093753279

Payments from drug & device makers

$358in general payments, 2019–2025

Across 20 payments — averaging $17.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$52
  • Boston Scientific$51
  • Regeneron Healthcare Solutions, Inc.$50
  • Inspire Medical Systems, Inc.$39
  • Shire North American Group Inc$37
  • Electromed, Inc.$34
  • plus $95 from 5 others

What the payments were for

  • Food & beverage$34697%
  • Education$123%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$358 in reported general payments places this provider in the 25th percentile of 904 pulmonary disease providers in Texas.

See all pulmonary disease providers in Texas

Medicare billing

Part B allowed, 2024
$142,724
Medicare patients
735
Services billed
1,405

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter187$171,478
Dupixent SyringeDupilumab26$107,685
Breo ElliptaFluticasone/Vilanterol146$77,057
EliquisApixaban58$47,601
SymbicortBudesonide/Formoterol Fumarate108$32,117
Spiriva RespimatTiotropium Bromide24$21,320
Spiriva HandihalerTiotropium Bromide33$19,721
Advair HfaFluticasone Propion/Salmeterol49$17,442
Stiolto RespimatTiotropium Br/Olodaterol Hcl18$15,828
Fluticasone-SalmeterolFluticasone Propion/Salmeterol79$13,929
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate38$12,875
XareltoRivaroxaban20$11,420
Combivent RespimatIpratropium/Albuterol Sulfate21$10,594
Albuterol Sulfate HfaAlbuterol Sulfate277$9,228
Bevespi AerosphereGlycopyrrolate/Formoterol Fum15$8,974

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta$52$263,269384 claims
AstraZenecaSymbicort, Bevespi Aerosphere$12$41,091123 claims
Johnson & JohnsonXarelto$34$11,42020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 904 pulmonary disease providers in Texas.

Other pulmonary disease in Bryan

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →